Navigation Links
Par Pharmaceutical Companies Reports Second Quarter 2011 Results
Date:8/3/2011

$84.5 million in the first quarter 2011. The decrease is due to primarily to the voluntary withdrawal of clonidine in the second quarter and the seasonality of hydrocodone/chlorpheniramine.
  • Megace® ES: Net sales were $14.1 million for the second quarter compared to $14.1 million in the first quarter.

  • Nascobal® B12 Nasal Spray: Net sales were $6.3 million for the second quarter compared to $3.9 million in the first quarter.  The increase was due, in part, to a shortage of a competing vitamin B12 intramuscular injection product.

  • Revenues and gross margin for the second quarter 2011 were $224.2 million and $99.0 million, respectively, compared to $233.0 million in net sales and $109.7 million in gross margin during the prior quarter (Q1 2011). The gross margin rate on the Company's consolidated product portfolio decreased to 44.2% versus 47.1% in the first quarter 2011.  The decrease was due primarily to the non-recurrence of the first quarter launches of propafenone and amlodipine/benazepril and the second quarter launch of lower margin budesonide.  2Q 20111Q 2011$%$%Key Par (Generic) Products (1)(2)$   40.7

    32.3%$   50.6

    40.4%All other Par (Generic)43.3

    56.5%42.0

    49.6%Total Par (Generic)$   84.0

    41.5%$   92.6

    44.1%Strativa (Branded) Products$   15.0

    69.1%$   17.1

    73.7%Total (All Products) $   99.0

    44.2%$ 109.7

    47.1%1. Q211 Key Par Products is comprised of Metoprolol, Budesonide EC, Sumatriptan, Propafenone, Amlodipine/benazapril, Meclizine.

    2. Q111 Key Par Products does not include Budesonide EC as it was launched in Q2.Operating ExpensesExcluding the one-time restructuring charge of $27.7 million, total operating expenses decreased during the second quarter of 2011 as compared to the prior quarter as follows:

  • Research and development expenses were $8.1 million in the seco
    '/>"/>

  • SOURCE Par Pharmaceutical Companies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
    2. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
    3. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
    4. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    5. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
    6. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
    7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
    9. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
    10. Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders
    11. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
    (Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
    (Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
    Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
    ... 28, 2011 Life Technologies Corporation (NASDAQ: ... Imaging Station , a revolutionary platform that eliminates the ... all scientists, regardless of their technical expertise.  A high-quality ... and printed directly from the platform,s printer or downloaded ...
    ... 28, 2011  Femina Pharma Incorporated announces the issuance of ... of Certain Vaginal Ring Birth Control Devices) by the ... Commission ("ITC") denying the Merck Respondents, Motion for Summary ... The issuance of Order 24 follows the prior issuance ...
    Cached Medicine Technology:Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 2Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 3Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 4Femina Pharma Announces ALJ's Denial of Merck's Motion for Summary Determination on Domestic Industry in ITC Patent Dispute Concerning NuvaRing® 2
    (Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
    (Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
    (Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
    (Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
    (Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
    Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
    ... Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical ... that they anticipate reporting top-line results from their current ... of 2009. , , The Phase ... trial to evaluate the efficacy and safety of Ketotransdel, ...
    ... High Resolution Monitoring of Drug Efficacy and Safety ... Based on its recent analysis in the ... & Sullivan recognizes Singulex, Inc. with the 2009 ... Innovation for pioneering the Erenna Immunoassay System. This ...
    ... NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the ... unaudited net sales results for May 2009 by segment are as follows: , , , ... NET SALES, ... (Preliminary and Unaudited), ...
    ... -- As the slumping economy continues to ... streamlining costs and creating additional efficiencies while continuing to ... those in need for charity care or self-pay discounts. ... landscape, TransUnion announced today new enhancements to its patented ...
    ... ... seniors nationwide. , ... (Vocus) June 15, 2009 -- VaxAmerica, a program of FFF Enterprises, Inc., ... into a partnership with Emeritus Senior Living. The alliance will encourage the 26,500 seniors ...
    ... ... have developed the strongest and most effective libido/intimacy enhancement therapy called VaietTM 110/L-Arginine for ... ... to announce the release of their exclusive Viagra/Arginine Intimacy Enhancement Therapy or VAIET (named ...
    Cached Medicine News:Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 2Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 4Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 3Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 4Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 2Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 3Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 2Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 2Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 4
    Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
    ... Double lumen ... one-lung ventilation., ... Tube is packaged ... tube-to-circuit adaptors, suction ...
    The TCB Univent® allows easily collapsing one lung for thoracoscopic procedures....
    ... Used for endobronchial blockade ... right lung for procedures ... The set consists of ... and an Arndt Multiport ...
    Medicine Products: